Document details

Mapping the diagnostic odyssey of congenital disorders of glycosylation (CDG)

Author(s): Granjo, Pedro ; Pascoal, Carlota ; Gallego, Diana ; Francisco, Rita ; Jaeken, Jaak ; Moors, Tristen ; Edmondson, Andrew C. ; Kantautas, Kristin A. ; Serrano, Mercedes ; Videira, Paula A. ; dos Reis Ferreira, Vanessa

Date: 2024

Persistent ID: http://hdl.handle.net/10362/180948

Origin: Repositório Institucional da UNL

Project/scholarship: info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F04378%2F2020/PT; info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F04378%2F2020/PT; info:eu-repo/grantAgreement/FCT/Concurso para Atribuição do Estatuto e Financiamento de Laboratórios Associados (LA)/LA%2FP%2F0140%2F2020/PT; info:eu-repo/grantAgreement/FCT//SFRH%2FBD%2F138647%2F2018/PT;

Subject(s): Community-centered research; Congenital disorders of glycosylation (CDG); Diagnostic odyssey journey; Patient journey; Rare diseases; Genetics(clinical); Pharmacology (medical)


Description

We would like to express our gratitude to the all CDG patient organizations and professionals who actively partnered with us in conducting this community-centered research led by the CDG & Allies \u2013 Patient Advocacy and International Research Network. We would also like to acknowledge the support of MetaBERN and FCDGC, as well as other CDG patient organizations worldwide, namely CDG Care, CDG Mexico, and Sindrome CDG, for disseminating the questionnaire of this study to various stakeholders of interest. Publisher Copyright: © The Author(s) 2024.

Background: Congenital disorders of glycosylation (CDG) are a group of rare metabolic diseases with heterogeneous presentations, leading to substantial diagnostic challenges, which are poorly understood. Therefore, this study aims to elucidate this diagnostic journey by examining families’ and professionals’ experiences. Results and discussion: A questionnaire was designed for CDG families and professionals, garnering 160 and 35 responses, respectively. Analysis revealed the lack of seizures as a distinctive feature between PMM2-CDG (11.2%) with Other CDG (57.7%) at symptom onset. Hypotonia and developmental disability were prevalent symptoms across all studied CDG. Feeding problems were identified as an early onset symptom in PMM2-CDG (Cramer’s V (V) = 0.30, False Discovery Rate (FDR) = 3.8 × 10− 9), and hypotonia in all studied CDG (V = 0.34, FDR = 7.0 × 10− 3). The average time to diagnosis has decreased in recent years (now ~ 3.9 years), due to advancements namely the increased use of whole genome and exome sequencing. However, misdiagnoses remain prevalent (PMM2-CDG – 44.9%, non-PMM2-CDG – 64.8%). To address these challenges, we propose adapting medical training to increase awareness of CDG and other rare diseases, ongoing education for physicians, the development of educational resources for relevant medical units, and empowerment of families through patient organizations and support networks. Conclusion: This study emphasizes the crucial role of community-centered research, and the insights families can offer to enhance CDG management. By pinpointing existing gaps and needs, our findings can inform targeted interventions and support systems to improve the lives of those impacted by CDG.

Document Type Journal article
Language English
Contributor(s) DCV - Departamento de Ciências da Vida; UCIBIO - Applied Molecular Biosciences Unit; Faculdade de Ciências e Tecnologia (FCT); RUN
facebook logo  linkedin logo  twitter logo 
mendeley logo

Related documents

No related documents